Home

William Grossman

CIK 1730229 · Interim Chief Medical Officer · last filed 2026-06-17

William Grossman is an Interim Chief Medical Officer who has filed 21 SEC Form 4 insider transactions across 4 companies since 2018. The most recent filing, for ENGNW, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$432.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $669.2K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$669.2K

Companies

4

Total Filings

21

Lifetime Open-Market Net

-$432.2K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ENGNW Interim Chief Medical Officer — $0.36 — $0 2 2026-06-17
Day One Biopharmaceuticals, Inc. (DAWN) Delisted Director — $21.53 — $0 5 2026-04-23
RCUS Chief Medical Officer 24,741 $27.05 $669.2K -$432.2K 11 2021-06-21
BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Sr. VP, Chief Medical Officer 2,687 $0.07 $201 $0 3 2019-02-07

Recent Filings

21 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-17 ENGNW Grant (A) — $0 EDGAR
2026-04-23 Day One Biopharmaceuticals, Inc. (DAWN) Delisted Disp (D) — $0 EDGAR
2025-11-07 Day One Biopharmaceuticals, Inc. (DAWN) Delisted Mixed — $0 EDGAR
2025-07-10 ENGNW Grant (A) — $0 EDGAR
2025-06-04 Day One Biopharmaceuticals, Inc. (DAWN) Delisted Grant (A) — $0 EDGAR
2024-05-28 Day One Biopharmaceuticals, Inc. (DAWN) Delisted Grant (A) — $0 EDGAR
2024-01-19 Day One Biopharmaceuticals, Inc. (DAWN) Delisted Grant (A) — $0 EDGAR
2021-06-21 RCUS Sell (S) −7,065 -$168.8K EDGAR
2021-04-26 RCUS Sell (S) −4,133 -$129.7K EDGAR
2021-03-18 RCUS Sell (S) −2,127 -$74.5K EDGAR
Showing 1–10 of 21
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.